Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. While hereditary forms account for 10-15% of cases, the majority of PD cases are sporadic, suggesting that environmental factors and epigenetic regulation play crucial roles in disease pathogenesis. Epigenetic modifications—heritable changes in gene expression without altering the DNA sequence—have emerged as critical regulators of PD susceptibility, progression, and phenotypic variability.
The reversible nature of epigenetic modifications makes them attractive therapeutic targets. Unlike genetic mutations, epigenetic changes can potentially be modulated through pharmacological interventions, lifestyle modifications, and targeted therapies. This page provides a comprehensive overview of epigenetic mechanisms in Parkinson's disease, including DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling.
Multiple epigenetic alterations have been documented in Parkinson's disease, affecting both the central nervous system and peripheral tissues. These changes contribute to:
Research has identified both disease-specific epigenetic signatures and therapeutic targets that could potentially modify disease progression.
DNA methylation involves the addition of a methyl group to cytosine residues in CpG dinucleotides, typically associated with gene silencing. In PD, both global and gene-specific methylation changes have been documented.
The SNCA gene encodes alpha-synuclein, the main component of Lewy bodies. DNA methylation at the SNCA intron 1 regulates its expression:
Several familial PD genes show altered methylation:
Environmental exposures modify PD risk through epigenetic mechanisms:
DNA methylation modifiers are being explored as disease-modifying therapies:
Histone modifications include acetylation, methylation, phosphorylation, ubiquitination, and sumoylation, dynamically regulating chromatin structure and gene expression.
Histone acetylation, primarily at lysine residues, is associated with transcriptional activation:
Different histone methylation marks have distinct effects:
| HDAC Class | Members | Role in PD |
|---|---|---|
| Class I | HDAC1, 2, 3, 8 | Transcriptional repression, neuronal survival |
| Class IIa | HDAC4, 5, 7, 9 | Activity-dependent gene regulation |
| Class IIb | HDAC6, 10 | Autophagy, aggresome clearance |
| Class III | SIRT1-7 | Mitochondrial function, stress response |
| Class IV | HDAC11 | Immune regulation |
The SIRT1 pathway is particularly relevant, with NAD+ precursor supplementation showing promise in PD models [26].
MicroRNAs (miRNAs), long non-coding RNAs (lncRNAs), and other non-coding RNAs regulate gene expression post-transcriptionally and play critical roles in PD pathogenesis.
| miRNA | Target | Function in PD |
|---|---|---|
| miR-30 | PINK1, LC3 | Mitophagy regulation |
| miR-181a | GRK2, α-syn | Dopaminergic dysfunction |
| miR-29 | DNMT3A | DNA methylation |
| miR-124 | ITPR2 | Calcium dysregulation |
Peripheral miRNAs show promise as PD biomarkers:
Chromatin remodeling complexes (SWI/SNF, ISWI, CHD, INO80) use ATP to slide, evict, or restructure nucleosomes, dynamically regulating gene accessibility.
Epigenetic clocks based on DNA methylation patterns estimate biological age:
Physical exercise has profound epigenetic effects in PD:
Epigenetic modifications serve as potential biomarkers for PD:
Epigenetic dysregulation in PD shares features with other neurodegenerative diseases:
Jowaed et al. SNCA methylation in Parkinson's disease (2010). 2010. ↩︎
Deshmukh et al. MeCP2 and SNCA regulation (2016). 2016. ↩︎
K或其它等, Pesticide exposure and DNA methylation (2018). 2018. ↩︎
Liu et al. LRRK2 methylation in PD (2019). 2019. ↩︎
Sung et al. PARKIN methylation in sporadic PD (2015). 2015. ↩︎
Pihlstrom et al. PINK1 epigenetic regulation (2017). 2017. ↩︎
Chuang et al. GBA methylation in PD (2019). 2019. ↩︎
Coupland et al. Global hypomethylation in PD brain (2014). 2014. ↩︎
Brenner et al. Blood methylation biomarkers in PD (2019). 2019. ↩︎
Horvath et al. Epigenetic clock in PD (2018). 2018. ↩︎
Kochel et al. Pesticide epigenetics in PD (2019). 2019. ↩︎
Oakes et al. Diet and methylation in PD (2017). 2017. ↩︎
Sung et al. Exercise and DNA methylation in PD (2020). 2020. ↩︎
Tremblay et al. DNMT inhibitors in PD models (2018). 2018. ↩︎
St Laurent et al. H3K9ac in PD (2013). 2013. ↩︎
Knott et al. HDAC inhibitors in PD (2015). 2015. ↩︎
Doi et al. HDAC6 and alpha-synuclein (2019). 2019. ↩︎
Swarbrick et al. H3K4me3 in PD (2019). 2019. ↩︎
Nicolas et al. H3K27me3 in neurodegeneration (2018). 2018. ↩︎
Matsumoto et al. H3K9me2 and stress response (2017). 2017. ↩︎
Ryu et al. H3S10 phosphorylation in PD (2018). 2018. ↩︎
Zhang et al. Aurora kinases in PD (2019). 2019. ↩︎
Heman-Ackah et al. Histone ubiquitination in PD (2017). 2017. ↩︎
Rott et al. Ubiquitination balance in PD (2018). 2018. ↩︎
Siddappa et al. SIRT1 and NAD+ in PD (2019). 2019. ↩︎
Junn et al. miR-7 and alpha-synuclein (2009). 2009. ↩︎
Minicione et al. miR-7 downregulation in PD (2019). 2019. ↩︎
Wang et al. miR-124 and neuronal survival (2018). 2018. ↩︎
Lou et al. miR-124 and microglia (2019). 2019. ↩︎
He et al. miR-124 and autophagy (2019). 2019. ↩︎
Zhang et al. miR-124 and synaptic function (2020). 2020. ↩︎
Hoss et al. miR-29 family in PD (2016). 2016. ↩︎
Roshan et al. miR-29 targets in PD (2019). 2019. ↩︎
Sznajder et al. NEAT1 in PD (2018). 2018. ↩︎
Chen et al. MALAT1 in neurodegeneration (2019). 2019. ↩︎
Zhao et al. HOTAIR in PD (2020). 2020. ↩︎
Kumar et al. circSNCA in PD (2018). 2018. ↩︎
Huang et al. circHIPK3 in PD (2019). 2019. ↩︎
Burgos et al. CSF miRNAs as biomarkers (2014). 2014. ↩︎
Botta-Orfila et al. Blood miRNA signatures in PD (2015). 2015. ↩︎
Ryu et al. SWI/SNF in PD (2014). 2014. ↩︎
Kelley et al. SWI/SNF and SNCA (2019). 2019. ↩︎
Matsumoto et al. nBAF complexes in neurons (2018). 2018. ↩︎
Witte et al. BAF and neurodegeneration (2019). 2019. ↩︎
Duan et al. NuRD complex in PD (2017). 2017. ↩︎
Zhang et al. NuRD and transcription (2020). 2020. ↩︎
Cao et al. H3.3 in neurodegeneration (2019). 2019. ↩︎
Kelley et al. H3.3 and neuronal gene expression (2020). 2020. ↩︎
Wu et al. SWI/SNF modulators (2019). 2019. ↩︎
Choudhury et al. CRISPR epigenome editing (2019). 2019. ↩︎
Lu et al. Epigenetic age acceleration in PD (2019). 2019. ↩︎
van den Hove et al. Epigenetic age and severity (2020). 2020. ↩︎
Chen et al. Epigenetic age and cognition (2020). 2020. ↩︎
Liu et al. Epigenetic age and treatment response (2021). 2021. ↩︎
Sung et al. Exercise reverses methylation (2020). 2020. ↩︎
Knott et al. Exercise and histone acetylation (2019). 2019. ↩︎
Mattson et al. Exercise and neurotrophic factors (2018). 2018. ↩︎
Pang et al. Exercise and miRNAs (2019). 2019. ↩︎
Monti et al. Valproic acid in PD (2015). 2015. ↩︎
Knott et al. SAHA neuroprotection (2017). 2017. ↩︎
Chen et al. Entinostat in PD models (2019). 2019. ↩︎
Tremblay et al. 5-azacytidine in PD (2018). 2018. ↩︎
Brunelli et al. RG108 in PD (2017). 2017. ↩︎
Junn et al. miR-7 therapeutic potential (2018). 2018. ↩︎
Kanagaraj et al. miR-124 therapy (2019). 2019. ↩︎
Zhang et al. Antagomir therapy in PD (2020). 2020. ↩︎
Liu et al. CRISPR-DNMT3A editing (2019). 2019. ↩︎
Hilton et al. CRISPR-p300 editing (2020). 2020. ↩︎
Sofola et al. Mediterranean diet epigenetics (2018). 2018. ↩︎
Pasinetti et al. Caloric restriction and sirtuins (2019). 2019. ↩︎
Wong et al. Stress and epigenetics (2019). 2019. ↩︎
Brenner et al. Blood methylation signatures (2019). 2019. ↩︎
Burgos et al. CSF miRNA progression markers (2016). 2016. ↩︎
Lu et al. Epigenetic age prediction (2019). 2019. ↩︎
Jakaria et al. MSA epigenetic signatures (2019). 2019. ↩︎
Yuan et al. PSP chromatin patterns (2020). 2020. ↩︎